...atazanavir messes up the kidneys...and most probably the secretion function and that is probably what is increasing Soraprevir plasma levels. Rito boosted ata also increases ALT levels in the liver by itself.
It is a sure thing. FDA and ACHN are just being overcautious. There were no SAEs with the combination. Atazanavir is a PI with non-specific and unknown mammalian protein targets. Ph2 combo of Soraprevir, ACHN3102, and ribavirin continues; that is the more important trial.
" The FDA has allowed continued enrollment and treatment of patients in the Phase 2 -007 clinical trial evaluating 12-weeks of sovaprevir in combination with ACH-3102 and ribavirin for patients with treatment-na�ve genotype 1 hepatitis C viral infection."